The absence of receptor downregulation or tolerance development in research suggests sustained effectiveness without the need for dose escalation over time
( ( We refer readers to the QualityNet website at for additional information on the reporting periods and submission deadlines for each measure finalized and proposed in the ASCQR Program
The SURMOUNT-1 trial demonstrated that participants on 15 mg tirzepatide lost an average of 20.9% of their body weight over 72 weeks
& Uthurusamy, R.) 446454 (New York, NY, 2013)
Cooperrider J, Furmaga H, Plow E, Park H-J, Chen Z, Kidd G, et al
For tendon injuries, subcutaneous (SubQ) injection is the highly recommended method